Preliminary analysis indicated a potential shared pathophysiological basis between POTS and anxiety disorders, with norepinephrine transporter proteins emerging as a significant therapeutic target for both conditions. This evidence concerns the gene SLC6A2 and postural orthostatic tachycardia syndrome.